Pharmaceutical Research Acute Heart Failure Therapeutics Market 2026 | Page 4

REPORT DESCRIPTION
Some of the key players in this market are Novartis AG, Cardiorentis AG, Bristol-Myers
Squibb Company, Amgen Inc., Bayer AG, Cytokinetics, Inc., Merck & Company, Inc., Ono
Pharmaceutical Co., Ltd., and Pfizer Inc., among others. Key players in the marker are
engaged in development of new drugs for acute heart failure (AHF). These players are
incorporating collaboration strategies to remain competitive in the market.
Request for TOC:
https://www.coherentmarketinsights.com/ongoing-insight/toc/1910
For instance, in October 2015, Cardiorentis AG announced plans to collaborate with Roche to
establish therapeutic efficacy and safety of Ularitide: Cardiorentis’ investigational drug for acute
heart failure (AHF). Under the terms of collaboration, Cardiorentis will incorporate Roche's
advanced in vitro diagnostic tests into its TRUE-AHF Phase III study to characterize the
pharmacological properties of Ularitide, evaluate its benefit-risk profile, and the appropriate
clinical application in patients.
© Coherent market Insights. All Rights Reserved